Related Experiment Videos
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant
M Fernandez-Guerrero1, M Rouse, N Henry
1Fundacion Jimenez Diaz, Madrid, Spain.
Abstract:
Ciprofloxacin was more effective (P less than 0.01) than either imipenem or nafcillin therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis in rabbits after 2 or 3 days of treatment. There was no significant difference between results of treatment of methicillin-susceptible S. aureus experimental endocarditis with ciprofloxacin and results with the combination of nafcillin and gentamicin. Ciprofloxacin was more effective (P less than 0.01) than vancomycin therapy of experimental methicillin-resistant S. aureus endocarditis after 3 days of treatment. After 5 days of treatment, there was no significant difference between the results of treatment of experimental methicillin-resistant S. aureus endocarditis with ciprofloxacin and results with vancomycin.
Insights
Ciprofloxacin demonstrated superior efficacy in treating methicillin-susceptible Staphylococcus aureus endocarditis in rabbits compared to imipenem or nafcillin. It also showed greater effectiveness against methicillin-resistant S. aureus than vancomycin in early treatment stages.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Bacterial endocarditis, particularly Staphylococcus aureus infections, poses a significant clinical challenge.
- Antibiotic resistance in S. aureus necessitates evaluating novel therapeutic strategies.
- Understanding the comparative efficacy of different antibiotics is crucial for effective treatment protocols.
Purpose of the Study:
- To compare the efficacy of ciprofloxacin against other antibiotics in treating experimental Staphylococcus aureus endocarditis.
- To evaluate treatment outcomes for both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of S. aureus.
Main Methods:
- An experimental endocarditis model was established in rabbits using S. aureus.
- Animals were treated with ciprofloxacin, imipenem, nafcillin, vancomycin, or a combination of nafcillin and gentamicin.
- Treatment efficacy was assessed after 2, 3, or 5 days based on predefined criteria.
Main Results:
- Ciprofloxacin showed significantly higher efficacy (P < 0.01) than imipenem or nafcillin against MSSA endocarditis after 2-3 days.
- No significant difference was observed between ciprofloxacin and nafcillin/gentamicin combination for MSSA endocarditis.
- Ciprofloxacin was significantly more effective (P < 0.01) than vancomycin against MRSA endocarditis after 3 days, with comparable results after 5 days.
Conclusions:
- Ciprofloxacin exhibits potent activity against experimental S. aureus endocarditis, including MRSA strains.
- The findings support ciprofloxacin as a potential therapeutic option for S. aureus endocarditis, warranting further clinical investigation.
- Comparative efficacy varies based on bacterial susceptibility and treatment duration.